Moderna Seeks FDA Nod For Updated COVID-19 Vaccine To Tackle Dominant Strain: The Hill
Portfolio Pulse from Benzinga Newsbot
Moderna has submitted an application to the FDA for authorization of its updated COVID-19 vaccine, designed to protect against the XBB.1.5 subvariant. The FDA advised vaccine manufacturers to target this subvariant in their fall vaccines, as it accounts for approximately 40% of U.S. cases.
June 22, 2023 | 11:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna submitted an application to the FDA for its updated COVID-19 vaccine targeting the XBB.1.5 subvariant, following FDA's recommendation to focus on this strain.
Moderna's updated vaccine targets the XBB.1.5 subvariant, which is currently the dominant strain in the U.S. The FDA's recommendation to focus on this strain and Moderna's quick response to update their vaccine could lead to increased demand and positive sentiment for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100